130 related articles for article (PubMed ID: 19606707)
1. [Oligosymptomatic alimentary tract perforation in course of Crohn's disease in patient treated with anti-TNF alfa antibodies].
Jałocha Ł; Wojtuń S; Wojtkowiak M; Błaszak A; Dyrla P; Gil J
Pol Merkur Lekarski; 2009 May; 26(155):491-2. PubMed ID: 19606707
[TBL] [Abstract][Full Text] [Related]
2. Anti tumour necrosis factor as risk factor for free perforations in Crohn's disease? A case-control study.
Eshuis EJ; Griffioen GH; Stokkers PC; Ubbink DT; Bemelman WA
Colorectal Dis; 2012 May; 14(5):578-84. PubMed ID: 21848898
[TBL] [Abstract][Full Text] [Related]
3. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.
Jürgens M; Brand S; Filik L; Hübener C; Hasbargen U; Beigel F; Tillack C; Göke B; Ochsenkühn T; Seiderer J
Inflamm Bowel Dis; 2010 Oct; 16(10):1634-6. PubMed ID: 20027647
[No Abstract] [Full Text] [Related]
4. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
5. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
6. First case report of adalimumab-induced psoriasis in Crohn's disease.
Harris MD; Richards R
Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
[No Abstract] [Full Text] [Related]
7. Closure of perianal fistula using adalimumab in a Crohn's disease patient naive to antitumor necrosis factor alpha antibodies.
Malesci A; Angelucci E; Bonifacio C; Sociale O; Omodei P; Repici A; Balzarini L; Danese S
Inflamm Bowel Dis; 2009 Jun; 15(6):814-5. PubMed ID: 18831523
[No Abstract] [Full Text] [Related]
8. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
Haennig A; Bonnet D; Thebault S; Alric L
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
[No Abstract] [Full Text] [Related]
9. [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology].
Reinisch W; Haas T; Kaser A; Petritsch W; Vogelsang H; Feichtenschlager T; Novacek G; Siebert F; Tilg H; Knoflach P
Z Gastroenterol; 2009 Apr; 47(4):372-80. PubMed ID: 19358065
[TBL] [Abstract][Full Text] [Related]
10. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.
Cravo M; Silva R; Serrano M
BioDrugs; 2010 Dec; 24 Suppl 1():25-7. PubMed ID: 21175232
[TBL] [Abstract][Full Text] [Related]
12. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
[TBL] [Abstract][Full Text] [Related]
13. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
Sorrentino D; Terrosu G; Vadalà S; Avellini C
Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
[No Abstract] [Full Text] [Related]
14. Patient outcomes after anti TNF-alpha drugs for Crohn's disease.
Assasi N; Blackhouse G; Xie F; Marshall JK; Irvine EJ; Gaebel K; Robertson D; Campbell K; Hopkins R; Goeree R
Expert Rev Pharmacoecon Outcomes Res; 2010 Apr; 10(2):163-75. PubMed ID: 20384563
[TBL] [Abstract][Full Text] [Related]
15. Development of the nephrotic syndrome during treatment of Crohn's disease with adalimumab.
Gupta A; Pendyala P; Arora P; Sitrin MD
J Clin Gastroenterol; 2011 Mar; 45(3):e30-3. PubMed ID: 20975576
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for cutaneous metastatic Crohn's disease.
Cury DB; Moss AC; Elias G; Nakao A
Inflamm Bowel Dis; 2010 May; 16(5):723-4. PubMed ID: 19728388
[No Abstract] [Full Text] [Related]
17. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
[No Abstract] [Full Text] [Related]
18. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
[TBL] [Abstract][Full Text] [Related]
19. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
20. Regression of Hodgkin lymphoma after discontinuation of a tumor necrosis factor inhibitor for Crohn's disease: a case report and review of the literature.
Cassaday RD; Malik JT; Chang JE
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):289-92. PubMed ID: 21658658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
